MODERNA (MRNA)
$26.70
0.03 (0.11%)
MRNA Stock Quote Delayed 30 Minutes
Moderna’s Stock Needs a Shot in the Arm
While MRNA stock has been trending higher in recent weeks, questions remain about Moderna's pipeline and senior management team.
Previous Close
$24.64
Market Cap
9.51B
PE Ratio
-2.88
EPS
-9.2737
Volume (Avg. Vol.)
13.08M
Day's Range
$23.68 - $27.68
52-Week Range
$23.15 - $170.47
Dividend & Yield
N/A (N/A)
MRNA Stock Predictions, Articles, and MODERNA News
The Freefall in Moderna Stock Will End Eventually
The discount in MRNA stock will not last forever given Moderna's steady cash flow growth potential from its Covid-19 vaccine.
Moderna’s Covid Shot Alone Isn’t Enough to Revitalize a Sagging Stock
Moderna has to focus on the rest of its pipeline to keep MRNA stock relevant and profitable as Covid vaccine revenues taper off by 2023.
Moderna Offers Deep Value as Drug Pipeline Flows Fast
MRNA stock has fallen into the buy zone, providing a prime opportunity as Moderna develops and commercializes multiple vaccine products.
Is Moderna the Next Gilead or the Next Regeneron?
MRNA stock is seen purely as a Covid-19 play. Until Moderna can prove it's not a one-hit wonder, shares are likely to remain depressed.
INTC Stock: 9 Things to Know About Mobileye’s Fully Autonomous Shuttles Coming in 2024
Intel (INTC) stock is on the move Monday after revealing plans for all-electric, autonomous vehicles that will hit public roads in 2024.
Is MRNA Stock a Buy Following 12% Plunge? 4 Analysts Weigh In.
Here's where the expert Wall Street analysts think Moderna and MRNA stock could be headed from here, following recent weakness.
Analysts See a Dip and Then a Rebound In Moderna’s Future
MRNA stock could be at full value here if analysts' projections for lower sales in 2023 come to pass, despite a potential rebound by Q4 2023.
Value Seekers Ought To Have Moderna on Their Radar Now
Even as MRNA stock plumbs new depths, Moderna's commitment to combat Covid-19 variant strains offers hope of a turnaround.
7 Hot Stocks to Pounce on if Their Prices Drop
Here are seven hot stocks that could provide investors with the long-term returns worth considering if their prices go down this year.
MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?
Vaccine stocks aren't enjoying a good morning today, but there's plenty of reason to suspect that they are in for a better year in 2022.
Moderna’s Long-Term Benefit Is Cursed by Short-Term Thinking
Moderna dropped after results for its mRNA flu vaccine underwhelmed investors. That proves MRNA stock is suffering from short-term thinking.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
